Chief Business Officer Naarden Van of Loxo Oncology Inc, unloaded 3,082 of the Pinksheet-listed company shares having an approx. value of $296,912 USD with an average of $96.3 stock price for a share. In the last month, he also sold 3,082 shares with a market value $271,866 USD. The trade was dated February 14, 2018 and was unveiled in a 4F filing filed with the SEC. The 4F filing is ready for use online here.

Since August 15, 2017, it had 0 buys, and 3 insider sales for $2.10 million activity. 2,634 shares valued at $140,793 were sold by Polipnick Gary A. on Friday, December 15. Miller Charles S. sold $1.48M worth of stock or 26,250 shares. 10,000 shares valued at $471,350 were sold by Hein LeLand J on Monday, October 16. DOLAN MICHAEL JOHN sold $344,080 worth of stock or 8,000 shares.

Investors sentiment increased to 1.3 in 2017 Q3. Its up 0.01, from 1.29 in 2017Q2. It improved, as 50 investors sold FAST shares while 161 reduced holdings. 62 funds opened positions while 213 raised stakes. 234.48 million shares or 1.45% more from 231.14 million shares in 2017Q2 were reported. Cetera Advisor Net Lc invested in 0.01% or 6,555 shares. M&T Savings Bank holds 65,851 shares. The Massachusetts-based Rhumbline Advisers has invested 0.06% in Fastenal Company (NASDAQ:FAST). Hightower Limited Co invested in 0.04% or 91,769 shares. Caxton Associates LP invested in 82,100 shares or 0.13% of the stock. Provident Trust holds 979,877 shares or 1.98% of its portfolio. American Intll Grp invested in 395,193 shares or 0.06% of the stock. Keybank Association Oh holds 0.01% in Fastenal Company (NASDAQ:FAST) or 32,605 shares. The California-based Mcdonald Cap Invsts Inc Ca has invested 8.89% in Fastenal Company (NASDAQ:FAST). California-based Schwab Charles Invest Management has invested 0.06% in Fastenal Company (NASDAQ:FAST). Yhb Inv Advisors reported 0.28% of its portfolio in Fastenal Company (NASDAQ:FAST). 13,414 are held by Comerica Inc. The Ontario – Canada-based Manufacturers Life Insurance Co The has invested 0.14% in Fastenal Company (NASDAQ:FAST). State Board Of Administration Of Florida Retirement Systems has invested 0.05% in Fastenal Company (NASDAQ:FAST). United Services Automobile Association stated it has 157,499 shares.

Among 17 analysts covering Fastenal (NASDAQ:FAST), 9 have Buy rating, 0 Sell and 8 Hold. Therefore 53% are positive. Fastenal had 63 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, January 19. BMO Capital Markets maintained the stock with “Hold” rating in Wednesday, January 17 report. On Wednesday, January 17 the stock rating was maintained by Robert W. Baird with “Buy”. On Wednesday, October 11 the stock rating was maintained by Stephens with “Buy”. Avondale upgraded Fastenal Company (NASDAQ:FAST) on Thursday, January 12 to “Mkt Outperform” rating. Argus Research initiated it with “Buy” rating and $57 target in Tuesday, March 8 report. The firm has “Neutral” rating by Macquarie Research given on Friday, August 26. Susquehanna maintained Fastenal Company (NASDAQ:FAST) on Thursday, January 18 with “Hold” rating. The firm has “Hold” rating given on Monday, January 8 by BMO Capital Markets. The stock of Fastenal Company (NASDAQ:FAST) earned “Neutral” rating by Sterne Agee CRT on Tuesday, March 22.

The stock increased 3.40% or $3.43 during the last trading session, reaching $104.35. About 504,068 shares traded or 25.37% up from the average. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 77.12% since February 15, 2017 and is uptrending. It has outperformed by 60.42% the S&P500.

Among 10 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Loxo Oncology Inc has $112.0 highest and $24 lowest target. $83.86’s average target is -19.64% below currents $104.35 stock price. Loxo Oncology Inc had 30 analyst reports since July 29, 2015 according to SRatingsIntel. As per Wednesday, March 16, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Cowen & Co with “Buy” on Monday, June 5. The rating was upgraded by Citigroup on Monday, June 5 to “Buy”. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Market Perform” rating by JMP Securities on Tuesday, August 29. The company was maintained on Monday, June 5 by Stifel Nicolaus. Citigroup maintained the shares of LOXO in report on Friday, October 20 with “Buy” rating. As per Wednesday, March 16, the company rating was maintained by Citigroup. On Tuesday, November 14 the stock rating was upgraded by JMP Securities to “Buy”. Citigroup initiated Loxo Oncology, Inc. (NASDAQ:LOXO) on Friday, January 15 with “Buy” rating. BTIG Research maintained it with “Buy” rating and $7500 target in Monday, June 5 report.

Since August 14, 2017, it had 0 insider purchases, and 18 insider sales for $70.60 million activity. On Thursday, December 14 Van Naarden Jacob sold $250,240 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) or 3,082 shares. Another trade for 10,000 shares valued at $751,731 was made by Kunkel Lori Anne on Tuesday, August 22. Bonita David P had sold 250,000 shares worth $20.63M. Burstein Jennifer sold $131,243 worth of stock or 1,500 shares. $523,883 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Flaherty Keith T. Bilenker Joshua H. also sold $1.22 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares. 250,000 shares were sold by ORBIMED ADVISORS LLC, worth $20.63M on Friday, December 8.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $3.12 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.